Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia

NCT03593213 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

587

Enrollment

INDUSTRY

Sponsor class

Stopped FDA Released Allergan from this post marketing requirement

Conditions

Schizophrenia

Interventions

DRUG: Cariprazine
DRUG: Placebo

Sponsor

AbbVie